Compare Enbridge Inc (ENB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Sanofi SA — how do they compare? Enbridge Inc trades at $56.23 (market cap $121.39B), while Sanofi SA trades at $44.1 (market cap $103.94B). The key difference: Enbridge Inc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| ENB | SNY | |
|---|---|---|
Market Cap | $121.39B | $103.94B |
Sector | Energy | Health |
52-Week High | $58.04 | $52.34 |
52-Week Low | $44.59 | $41.33 |
Enterprise Value | $202.19B | $120.43B |
Dividend Yield | 5.01% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $55.89, up 1.49% recently, with technical indicators showing a bullish trend. The company reported strong Q1 2026 earnings, beating estimates with $0.71 EPS, and maintains a robust dividend. Revenue grew to $65.19B in 2025, with net income of $7.49B, though valuation ratios like a P/E of 27.02 appear elevated relative to historical norms. Analyst sentiment is mixed with a 48% buy rating, while recent news highlights the company's $28B growth project pipeline and its positioning as a defensive, high-yield stock amid market volatility.
The outlook for ENB is balanced: growth projects and consistent cash flow support dividend sustainability, offering a defensive yield in uncertain markets. However, risks include high leverage, sensitivity to interest rates, and execution challenges on capital projects. The stock's current valuation may limit near-term upside, making it more suitable for income-focused investors rather than those seeking rapid growth.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
